MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
20.94
+0.62
+3.05%
After Hours: 20.30 -0.64 -3.06% 17:54 06/21 EDT
OPEN
20.38
PREV CLOSE
20.32
HIGH
21.26
LOW
20.38
VOLUME
2.55M
TURNOVER
0
52 WEEK HIGH
24.17
52 WEEK LOW
7.41
MARKET CAP
1.60B
P/E (TTM)
-9.6249
1D
5D
1M
3M
1Y
5Y
Kura Oncology Price Target Maintained With a $32.00/Share by JMP Securities
Dow Jones · 3d ago
JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
Benzinga · 3d ago
Buy Rating Affirmed on Kura Oncology Amid Promising Clinical Trials and Strong Financials
TipRanks · 4d ago
Weekly Report: what happened at KURA last week (0610-0614)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and HCA Healthcare (HCA)
TipRanks · 06/13 13:30
KURA ONCOLOGY INC <KURA.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $35 FROM $33
Reuters · 06/13 10:38
U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. Avidity Biosciences, Broadcom, Cara Therapeutics and 3M among companies. 3M raises to outperform from peer perform. Boeing, Amphenol and Boeing among companies with research actions on Thursday.
Reuters · 06/13 07:24
Dynavax, Bloomin Brands, and Premier are the most shorted small-cap stock in May - Hazeltree report
Dynavax, Bloomin Brands, and Premier are the most shorted small-cap stock in May - Hazeltree report. DVAX, BLMN, and PINC are down nearly 32% and 17.5% year-to-date.
Seeking Alpha · 06/11 16:40
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Webull offers Kura Oncology Inc stock information, including NASDAQ: KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.